Johnson&Johnson reports Q3 beat, raises sales guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. SPY
3. FDX
4. META
5. ABBV
6. ACN
7. BLZE
8. IBM
9. NKE
10. MU

Go back to Johnson&Johnson reports Q3 beat, raises sales guidance

Johnson & Johnson (JNJ) PT Raised to $181 at RBC Capital

October 16, 2024 6:50 AM EDT

RBC Capital analyst Shagun Singh raised the price target on Johnson & Johnson (NYSE: JNJ) to $181.00 (from $178.00) while maintaining a Outperform rating.

The analyst comments "JNJ delivered a Q3 beat on sales/EPS that sent the stock up ~2% today. The company delivered +5.6% y/y underlying... More

Johnson & Johnson (JNJ) PT Raised to $170 at Stifel

October 15, 2024 2:22 PM EDT

Stifel analyst Rick Wise raised the price target on Johnson & Johnson (NYSE: JNJ) to $170.00 (from $160.00) while maintaining a Hold rating.

The analyst comments "Helped by better-than-expected 3Q24 Pharmaceutical division performance, both JNJ 3Q24 sales and EPS outperformed Stifel and consensus. And looking ahead, the company's... More

Citi Reiterates Buy Rating on Johnson & Johnson (JNJ)

October 15, 2024 8:20 AM EDT

Citi analyst Joanna Wuensch reiterated a Buy rating and $180.00 price target on Johnson & Johnson (NYSE: JNJ).

The analyst comments "JNJ delivered 3Q24 revenue of $22.5B (up 5.6% organic) ahead of consensuss $22.2B. Innovative Medicine sales were $14.58B (up 6.7% organic ex-Covid-19, versus consensuss... More